Microsoft word - document15

The Southwest Oncology Group Invites You to Attend the Spring 2007 Group Meeting At the Hyatt Regency Hotel in Chicago, Illinois To register for the meeting, review the schedule, plan your travel, and view details of the Group Meeting please use the link below. Also don’t miss our Plenary Session on Saturday, May 5, 2007, from 8:30 - 11:00 a.m. The highlight this year for the plenary session is Innovation for Increased
We all know, for example, the Europeans are currently conducting Phase III
trials more efficiently than Americans. The plenary presentations will focus on recent studies
completed through successful collaborations and/or innovative approaches. SWOG Group Chair
Laurence Baker, DO, will also give a presentation, “Strategic Response to Budget Cuts.” And as
always, there will be a few surprises!
Abstracts illustrating innovative approaches include:
S0124: Randomized Phase III Trial of Cisplatin and Irinotecan versus Cisplatin and
Etoposide in Patients with Extensive Stage Small Cell Lung Cancer
Presenter: Primo Lara, Jr, MD, UC Davis Cancer Center
C9710: Phase III Randomized Study of Concurrent Tretinoin and Chemotherapy With or
Without Arsenic Trioxide (AS2O3) (NSC #706363) as Initial Consolidation Therapy
Followed by Intermittent Tretinoin Maintenance Therapy Versus Observation for Patients
with Untreated Acute Promyelocytic Leukemia
Presenter: Steven Coutre, MD, Stanford University
S0205: A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus
Cetuximab (IMC-C225) Versus Gemcitabine as First-Line Therapy of Patients with
Advanced Pancreas Cancer
Presenter: Phillip Phillip, MD, PhD, Karmanos Cancer Center
S8897: Pharmacogenetics and Breast Cancer Treatment Outcomes: Results on
Oxidative Stress Related Genotypes (MPO, MnSOD) from a Southwest Oncology Group
Intergroup Trial
Presenter: Christine Ambrosone, PhD, Roswell Park Cancer Institute

Discussants include Fred Appelbaum, MD, Fred Hutchinson Cancer Center; Joe Nevins, PhD,
Duke University; Peter O’Dwyer, MD, University of Pennsylvania; Richard Schilsky, MD, CALBG,
University of Chicago; and other internationally renowned experts.
Our Translational Medicine Meeting, Friday, May 4, 4:30 - 6:00 p.m., will offer Translational
Medicine Strategies for Patient Enrichment.
Speakers include Joe Nevins, PhD, Director of the
IGSP Center for Genome Technology at Duke University; Peter O’Dwyer, MD, Experimental
Therapeutics Director at the University of Pennsylvania Cancer Center; and John Crowley, PhD,
SWOG Group Biostatistician and Director of the SWOG Statistical Center and Data Operations
For more information about the upcoming meeting, please see our Group Meeting News at
We look forward to your participation in the SPRING 2007 SWOG GROUP MEETING!



El síncope, que se define como la pérdida brusca y con recuperación es-pontánea de la conciencia debida a caída de la perfusión cerebral. Es por lotanto una pérdida del estado conciencia y el tono postural transitorio que norequiere de maniobras especiales para su recuperación. Debido a la condi-ción de recuperación espontánea, el síncope no es mortal, pero si valor pro-nóstico con r

Lppa 01.2014

Name / Nom /Cl.Thér. EAN-Nr / Nr.EAN ACTIVITAL forte Brause Plv orange limet Btl 10 StkACTIVITAL forte Brause Plv orange limet Btl 20 StkAMAVITA Vitacen Multivitamin Brausetabl 10 Stk ARKOCAPS Ispaghul Indischer Flohsamen Kaps 50 Stk ARKOCAPS Sojalezithine und Safloröl Kaps 50 StkBEKUNIS Abführtee tassenfertig Glas 150 ml ©Fachgrouppe LPPV / Groupe d'experts LPPABEROCCA Calc M

Copyright © 2010 Medicament Inoculation Pdf